文献速递心脑血管急症重症综合管理与镇静镇痛

评估效用加权改良Rankin量表作为蛛网膜下腔出血临床试验结局的效用:SAHaRA二次分析

Evaluating Utility-Weighted Modified Rankin Scale as an Outcome for Clinical Trials in Subarachnoid Hemorrhage: A SAHaRA Secondary Analysis.
PubMed 文献 · Neurocrit Care · 2026-07-17
一句话结论在aSAH患者中,UW-mRS与二分类mRS结果一致,保留更多以患者为中心的信息,且与患者报告结局拟合更优,但未显著提高统计效能。

本研究为SAHaRA随机临床试验的二次分析,纳入725例动脉瘤性蛛网膜下腔出血患者,将mRS各分类映射为效用加权评分(UW-mRS),并比较二分类mRS、序数mRS和UW-mRS三种分析方法的效能。12个月时,宽松输血组mRS≥4的比例为33.5%,限制性组为37.7%(OR 0.88,95%CI 0.72-1.07,p=0.24);UW-mRS均值分别为0.55±0.39和0.52±0.39(β=0.04,95%CI -0.02-0.09,p=0.22)。效能计算显示,二分类mRS每组需1900例,序数mRS需1450例,UW-mRS需1460例。UW-mRS与患者报告结局的拟合优度更好。

要点

  • 在aSAH患者中,UW-mRS与二分类mRS分析结果一致:宽松输血组12个月mRS≥4为33.5%,限制性组为37.7%(OR 0.88,95%CI 0.72-1.07,p=0.24)。
  • UW-mRS均值:宽松输血组0.55±0.39,限制性组0.52±0.39(线性回归β=0.04,95%CI -0.02-0.09,p=0.22)。
  • 效能计算(80%效能,α=0.05)显示,重复SAHaRA所需样本量:二分类mRS每组1900例,序数mRS每组1450例,UW-mRS每组1460例。
  • UW-mRS保留了更多以患者为中心的信息,且与患者报告结局的拟合优度优于二分类mRS。
  • SAHaRA重算的效用权重与既往缺血性卒中试验中发表的权重高度匹配。

适用人群与场景

  • 动脉瘤性蛛网膜下腔出血(aSAH)患者,来自SAHaRA随机临床试验的二次分析,共725例参与者。

诊断标准与关键阈值

  • 结局评估工具:效用加权改良Rankin量表(UW-mRS),通过将每个mRS分类映射为患者报告的效用评分计算,评分越高结局越好;同时使用既往发表的效用权重进行验证。
  • 预设不良结局定义为mRS≥4。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:SAHaRA随机临床试验的二次分析;样本量725例参与者;人群为动脉瘤性蛛网膜下腔出血患者。
  • 干预与对照:SAHaRA试验中的宽松输血策略 vs 限制性输血策略。
  • 主要终点结果:12个月时,宽松输血组33.5%达到预设不良结局(mRS≥4),限制性组37.7%(OR 0.88,95%CI 0.72-1.07,p=0.24)。
  • UW-mRS结果:宽松输血组平均0.55±0.39,限制性组0.52±0.39(线性回归β=0.04,95%CI -0.02-0.09,p=0.22)。
  • 效能计算:假设80%效能和α=0.05,重复SAHaRA所需样本量二分类mRS每组1900例,全序数mRS每组1450例,UW-mRS每组1460例。
  • UW-mRS对次要患者报告结局的拟合优度更好。

证据类型、等级与局限

  • 证据类型:随机临床试验(SAHaRA)的二次分析。
  • 局限:为二次分析;原文未提及其它局限。

对床旁实践的改变

  • 在aSAH临床试验中,UW-mRS可作为二分类mRS的替代结局指标,结果一致且保留更多患者中心信息,但与患者报告结局拟合更优;UW-mRS未显著提高统计效能(每组需1460例 vs 二分类mRS 1900例,序数mRS 1450例)。
  • 适用人群:动脉瘤性蛛网膜下腔出血患者;不适用人群原文未提及。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

INTRODUCTION: The utility-weighted modified Rankin Scale (UW-mRS) is an emerging alternative to the traditional ordinal mRS as a patient-centered measure of functional outcome in clinical trials. As a quasi-continuous parameter, the UW-mRS has been shown to better represent patient-centered outcomes and enable more efficient power calculations in acute ischemic stroke studies. However, its utility has not yet been tested in patients with subarachnoid hemorrhage (SAH).

METHODS: In a secondary analysis of the aneurysmal SubArachnoid Hemorrhage - Red blood cell transfusion And outcome (SAHaRA) randomized clinical trial, the UW-mRS, where higher scores reflect better outcomes, was computed by mapping each mRS category using utility scores reported by the patients, and in addition, using previously published utility weights to validate these weights in this population. The primary and secondary outcomes of SAHaRA were analyzed with the UW-mRS. Power calculations were compared across three possible outcome analytic approaches: binary mRS, ordinal mRS, and UW-mRS.

RESULTS: A total of 725 participants were included. Recalculated utility-weights from SAHaRA closely matched those previously published in ischemic stroke trials. At 12 months, 33.5% of patients in the liberal transfusion arm achieved the predefined unfavorable outcome (mRS ≥ 4) versus 37.7% in the restrictive arm (odds ratio [OR] 0.88, 95% confidence interval [CI] 0.72-1.07, p = 0.24). Using the UW-mRS, the average ± standard deviation in the liberal arm was 0.55 ± 0.39 compared with 0.52 ± 0.39 (linear regression β = 0.04, 95% CI - 0.02-0.09, p = 0.22). Power calculations, assuming 80% power and α = 0.05, indicated that replicating SAHaRA with dichotomized mRS would require 1900 participants per group, 1450 per group with the full-ordinal mRS, and 1460 per group with the UW-mRS. The UW-mRS demonstrated better goodness-of-fit to secondary patient-reported outcomes.

CONCLUSIONS: The UW-mRS yielded results consistent with dichotomized mRS while preserving more patient-centered information, improving statistical efficiency, and showing stronger agreement with patient-reported outcomes.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Sadan O, Yu Z, Ma T, et al. Evaluating Utility-Weighted Modified Rankin Scale as an Outcome for Clinical Trials in Subarachnoid Hemorrhage: A SAHaRA Secondary Analysis. Neurocrit Care. 2026. PMID: 42469581. doi:10.1007/s12028-026-02589-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。